Wells Fargo’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-40
| Closed | -$60 | – | 7819 |
|
|
2023
Q2 | $60 | Hold |
40
| – | – | ﹤0.01% | 7012 |
|
|
2023
Q1 | $70 | Buy |
40
+35
| +700% | +$59 | ﹤0.01% | 7023 |
|
|
2022
Q4 | $9 | Sell |
5
-6
| -55% | -$13 | ﹤0.01% | 7386 |
|
|
2022
Q3 | $0 | Buy |
11
+6
| +120% | +$25 | ﹤0.01% | 7945 |
|
|
2022
Q2 | $0 | Buy |
+5
| New | +$33 | ﹤0.01% | 8041 |
|
|
2022
Q1 | – | Sell |
-13
| Closed | – | – | 8372 |
|
|
2021
Q4 | $0 | Hold |
13
| – | – | ﹤0.01% | 8326 |
|
|
2021
Q3 | $0 | Hold |
13
| – | – | ﹤0.01% | 7959 |
|
|
2021
Q2 | $0 | Hold |
13
| – | – | ﹤0.01% | 7917 |
|
|
2021
Q1 | $1K | Sell |
13
-566
| -98% | -$35.2K | ﹤0.01% | 6831 |
|
|
2020
Q4 | $35K | Sell |
579
-225
| -28% | -$24.4K | ﹤0.01% | 5708 |
|
|
2020
Q3 | $108K | Buy |
804
+305
| +61% | +$51K | ﹤0.01% | 5234 |
|
|
2020
Q2 | $84K | Buy |
499
+57
| +13% | +$9.51K | ﹤0.01% | 5305 |
|
|
2020
Q1 | $64K | Buy |
442
+98
| +28% | +$30K | ﹤0.01% | 5262 |
|
|
2019
Q4 | $114K | Sell |
344
-15
| -4% | -$6.88K | ﹤0.01% | 5233 |
|
|
2019
Q3 | $179K | Buy |
359
+80
| +29% | +$45.1K | ﹤0.01% | 5024 |
|
|
2019
Q2 | $169K | Buy |
+279
| New | +$171K | ﹤0.01% | 5064 |
|
|
2018
Q4 | – | Sell |
-32
| Closed | -$22K | – | 6732 |
|
|
2018
Q3 | $22K | Buy |
32
+31
| +3,100% | +$22K | ﹤0.01% | 5813 |
|
|
2018
Q2 | $1K | Hold |
1
| – | – | ﹤0.01% | 6281 |
|
|
2018
Q1 | $1K | Hold |
1
| – | – | ﹤0.01% | 6310 |
|
|
2017
Q4 | $1K | Hold |
1
| – | – | ﹤0.01% | 6295 |
|
|
2017
Q3 | $2K | Buy |
+1
| New | +$2.35K | ﹤0.01% | 6184 |
|
|
2017
Q2 | – | Hold |
0
| – | – | – | 6160 |
|
Wells Fargo's NBRV Position: Q3 2023 in Review
Wells Fargo sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q3 2023, closing a stake of 40 shares — an estimated $60 sold.
Wells Fargo first reported a position in NBRV in Q3 2017 and held it in 21 quarters. The position peaked at $179K in Q3 2019. 0 funds tracked by Wall St. Rank hold NBRV as of Q3 2023.
- Wells Fargo reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q3 2023 after selling out during the quarter.
- Wells Fargo sold 40 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q3 2023, an estimated $60.
- Wells Fargo first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q3 2017 and held it in 21 quarters.
- Wells Fargo's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $179K in Q3 2019.
- 0 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q3 2023.
Based on Wells Fargo's 13F filing for Q3 2023, filed 13 Nov 2023.